Characteristics of 21 patients with leukemia and their respective donors
Patient no. . | Age, y . | Sex . | Disease . | Prior therapy . | Disease risk . | Donor age, y . | Donor sex . | CSA . | CD34 dose, × 106 cells/kg . | CD3 dose, × 104 cells/kg . | DLI . | Max grade of GVHD . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 44 | F | AML | Y | HR | 44 | F | N | 5.82 | 2 | 45 | 2 |
| 2 | 31 | M | AML | Y | HR | 20 | F | N | 4.78 | 2 | 45 | 2 |
| 3 | 16 | F | AML | Y | LR | 15 | F | N | 3.339 | 2 | 45 | 2 |
| 4 | 29 | M | AML | Y | LR | 28 | F | Y | 5.98 | 2 | 60 | 2 |
| 5 | 36 | F | AML | Y | HR | 33 | F | Y | 4.98 | 2 | 60 | 1 |
| 6 | 32 | F | AML | Y | LR | 34 | M | Y | 6.59 | 2 | 100 | 2 |
| 7 | 45 | M | CLL | Y | HR | 46 | M | Y | 7.04 | 2 | 60 | 2 |
| 8 | 10 | M | ALL | Y | HR | 17 | F | Y | 5.26 | 2 | 60 | 0 |
| 9 | 16 | M | AML | Y | HR | 18 | F | Y | 10.05 | 2 | No | 4 |
| 10 | 38 | F | AML | Y | LR | 42 | F | Y | 3.2 | 10 | 100 | 3 |
| 11 | 30 | M | CML | Y | HR | 37 | M | N | 6.62 | 2 | No | 4 |
| 12 | 26 | F | AML | Y | HR | 32 | M | N | 5.9 | 2 | No | 4 |
| 13 | 37 | M | CLL | Y | HR | 45 | M | Y | 15.9 | 2 | No | 0 |
| 14 | 42 | F | CML | Y | HR | 47 | M | N | 5.65 | 2 | No | 4 |
| 15 | 27 | F | ALL | Y | HR | 25 | F | Y | 4.95 | 2 | 45 | 0 |
| 16 | 35 | F | AML | N | HR | 31 | F | N | 7.65 | 2 | No | 3 |
| 17 | 18 | F | CML | Y | LR | 27 | F | N | 7.22 | 2 | No | 3 |
| 18 | 19 | M | ALL | Y | HR | 19 | M | Y | 5.03 | 2 | 63 | 2 |
| 19 | 40 | M | CML | Y | LR | 44 | F | N | 6.94 | 2 | 48 | 0 |
| 20 | 17 | M | ALL | Y | HR | 18 | F | N | 7.2 | 2 | 45 | 1 |
| 21 | 32 | M | AML | Y | LR | 30 | F | N | 4.36 | 2 | 45 | 2 |
Patient no. . | Age, y . | Sex . | Disease . | Prior therapy . | Disease risk . | Donor age, y . | Donor sex . | CSA . | CD34 dose, × 106 cells/kg . | CD3 dose, × 104 cells/kg . | DLI . | Max grade of GVHD . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 44 | F | AML | Y | HR | 44 | F | N | 5.82 | 2 | 45 | 2 |
| 2 | 31 | M | AML | Y | HR | 20 | F | N | 4.78 | 2 | 45 | 2 |
| 3 | 16 | F | AML | Y | LR | 15 | F | N | 3.339 | 2 | 45 | 2 |
| 4 | 29 | M | AML | Y | LR | 28 | F | Y | 5.98 | 2 | 60 | 2 |
| 5 | 36 | F | AML | Y | HR | 33 | F | Y | 4.98 | 2 | 60 | 1 |
| 6 | 32 | F | AML | Y | LR | 34 | M | Y | 6.59 | 2 | 100 | 2 |
| 7 | 45 | M | CLL | Y | HR | 46 | M | Y | 7.04 | 2 | 60 | 2 |
| 8 | 10 | M | ALL | Y | HR | 17 | F | Y | 5.26 | 2 | 60 | 0 |
| 9 | 16 | M | AML | Y | HR | 18 | F | Y | 10.05 | 2 | No | 4 |
| 10 | 38 | F | AML | Y | LR | 42 | F | Y | 3.2 | 10 | 100 | 3 |
| 11 | 30 | M | CML | Y | HR | 37 | M | N | 6.62 | 2 | No | 4 |
| 12 | 26 | F | AML | Y | HR | 32 | M | N | 5.9 | 2 | No | 4 |
| 13 | 37 | M | CLL | Y | HR | 45 | M | Y | 15.9 | 2 | No | 0 |
| 14 | 42 | F | CML | Y | HR | 47 | M | N | 5.65 | 2 | No | 4 |
| 15 | 27 | F | ALL | Y | HR | 25 | F | Y | 4.95 | 2 | 45 | 0 |
| 16 | 35 | F | AML | N | HR | 31 | F | N | 7.65 | 2 | No | 3 |
| 17 | 18 | F | CML | Y | LR | 27 | F | N | 7.22 | 2 | No | 3 |
| 18 | 19 | M | ALL | Y | HR | 19 | M | Y | 5.03 | 2 | 63 | 2 |
| 19 | 40 | M | CML | Y | LR | 44 | F | N | 6.94 | 2 | 48 | 0 |
| 20 | 17 | M | ALL | Y | HR | 18 | F | N | 7.2 | 2 | 45 | 1 |
| 21 | 32 | M | AML | Y | LR | 30 | F | N | 4.36 | 2 | 45 | 2 |
DLI indicates donor lymphocyte infusion; F, female; HR, high risk; M, male; LR, low risk; Cy, cyclophosphamide; CSA, cyclosporine A.